Vendor Selection

Document specific biological question, organ/tissue type, complexity level, throughput needs (low/medium/high), endpoints (viability, biomarkers, imaging), study timeline, regulatory requirements, and budget constraints. Create vendor requirements document (VRD) with must-have vs. nice-to-have features. Obtain stakeholder sign-off before initiating vendor search.

Systematically identify potential vendors through: literature search (PubMed, company websites), conference attendance (SOT, ASCCT, Organ-on-Chip World Summit), industry directories (IQ MPS Affiliate members), and peer recommendations. Create long list of 8-12 potential vendors. Research each vendor's technology platform, validation status, customer base, and business model.

Send structured RFI to shortlisted vendors requesting: technology overview, performance specifications, validation data, case studies in similar applications, pricing structure (equipment, consumables, services), delivery timelines, support model, and quality certifications. Include NDA to protect proprietary information exchange. Set response deadline (2-3 weeks).

Schedule 90-minute presentations/demos from top 3-4 vendors based on RFI responses. Include cross-functional team (scientists, quality, procurement). Request live demonstration or video of platform operation. Vendors should address your specific application with relevant data. Allocate time for detailed Q&A on technical, commercial, and quality aspects. Document all claims for later verification.

Issue formal Request for Proposal (RFP) to 2-3 finalists with your exact project specifications. Request: detailed technical proposal, statement of work, itemized pricing (equipment, consumables, training, support), delivery schedule, payment terms, warranty/guarantees, and draft contract. Specify evaluation criteria and decision timeline. Request budget pricing for future scale-up scenarios to assess long-term economics.

Request 3-5 reference customers working in similar applications (organ type, complexity, regulatory path). Conduct structured reference calls asking: performance vs. expectations, reproducibility, vendor responsiveness to issues, hidden costs, training effectiveness, and would-you-buy-again rating. Request both successful implementations AND ask vendor about customers who discontinued use and why (red flag if they refuse).

For CRO services or major platform purchases (>$250K), visit vendor facilities to assess: operational capabilities, equipment condition/maintenance, staff expertise and turnover, quality systems implementation, sample/data archiving, security/confidentiality controls. Observe actual operations (not just demo lab). Interview technical staff who will execute your studies. Review QC data from recent customer projects.

Evaluate vendor's published validation data for: sample size (n=3 biological replicates?), statistical rigor (appropriate power analysis?), reproducibility demonstration (inter-batch, inter-operator, inter-site), benchmark against standard methods (correlation to in vivo or clinical data), and author conflicts of interest (vendor-funded vs. independent validation). Strong preference for peer-reviewed publications over white papers or conference abstracts.

Calculate 3-5 year TCO including: upfront equipment ($0 for CRO, $50K-$500K+ for purchase), annual consumables (plates, media, matrices, reagents), service/maintenance contracts, training and onboarding, internal FTE costs (if running in-house), facility costs (incubator space, storage), and potential revalidation costs. Compare TCO per data point across vendors and vs. traditional methods to justify investment.

Clarify in contract: data ownership (you retain all rights to generated data), publication rights (can you publish without vendor approval/co-authorship?), background IP (vendor platform) vs. foreground IP (discoveries using platform), confidentiality terms, and data portability (can you take data/samples to another vendor?). Some vendors claim rights to discoveries—unacceptable for most pharma/biotech. Get Legal review before signing.

For long-term partnerships, assess vendor viability: funding status (runway >18 months?), revenue trajectory, customer base size/diversity, venture backing quality, M&A rumors, and product roadmap commitment. Vendor bankruptcy or acquisition mid-project creates major disruption. For startups, request: most recent funding round details, burn rate, and contingency plan for consumable supply if company fails. Consider requiring escrow for critical reagents/cells.

CRITICAL STEP: Always run pilot study before full commitment. Define clear success criteria: technical (reproducibility, sensitivity, dynamic range), operational (turnaround time, ease of use), and analytical (data quality, biological relevance). Include positive/negative controls and reference compounds with known biology. Ideally test with your actual samples/compounds under NDA. Budget $15K-$50K for meaningful pilot. Failed pilot is cheap compared to failed program.

Analyze pilot data against pre-defined success criteria—resist temptation to "move goalposts" if vendor relationship is otherwise attractive. Key metrics: inter-replicate CV% (<20% for most assays), Z' factor (>0.5 for screening), EC50 reproducibility (within 3-fold of reference), correlation to benchmark method (R²>0.7), and sensitivity to detect expected biology. Present results to stakeholders for go/no-go decision. Document decision rationale regardless of outcome.

Negotiate master service agreement (MSA) or purchase agreement with: detailed scope of work, performance specifications (matching pilot results), acceptance criteria for deliverables, payment terms tied to milestones, confidentiality/IP clauses, termination rights (for cause and convenience), liability caps, audit rights, and dispute resolution. Include service level agreements (SLAs) for CRO work: turnaround times, communication protocols, escalation procedures. Have Legal review thoroughly.

For in-house platforms: schedule installation qualification (IQ), operational qualification (OQ), and comprehensive user training (theory + hands-on). Require vendor to train multiple users (2-3 minimum) to avoid single-person dependency. Document all training with sign-off sheets and competency assessment. For CRO services: hold project kickoff meeting defining communication cadence, data delivery formats, and escalation contacts. Establish shared project management tools (SharePoint, Benchling).

Implement vendor scorecard tracking: technical performance (data quality metrics, repeat rate, failure modes), operational performance (on-time delivery, responsiveness, protocol adherence), quality performance (deviations, CAPA closure time), and commercial performance (invoice accuracy, change order frequency). Review quarterly with vendor in business review meetings. Use data to identify improvement opportunities or trigger termination clauses if performance degrades.

Before signing contract, document contingency plan if vendor relationship fails: Can you transfer to alternative vendor? (assess compatibility of platforms/data formats). Can you bring capability in-house? (equipment availability, staff expertise). Can you revert to previous method? Include contract clauses enabling transition: data portability in standard formats, return of proprietary materials/samples, knowledge transfer assistance, non-exclusivity for multi-vendor strategy.

Create formal vendor qualification report documenting: selection process, evaluation criteria, vendors considered, scoring results, pilot study outcomes, reference check summaries, financial/risk assessment, contract highlights, and final recommendation with rationale. Obtain sign-off from stakeholders (R&D head, Quality, Procurement). File in vendor qualification system per QMS requirements. This documentation is critical for regulatory audits—demonstrates systematic, science-based vendor selection.

The Pilot Study is Non-Negotiable

"We've evaluated 50+ organoid vendors over 10 years. The ONLY reliable predictor of success is a well-designed pilot study with YOUR compounds and YOUR success criteria. Marketing claims, publications, even customer references—all are poor substitutes for hands-on data. Budget $25K-$50K for meaningful pilot testing 10-15 samples with positive/negative controls. The pilot that 'fails' and saves you from a bad vendor is the best money you'll ever spend."
Dr. Rachel Kim, VP Discovery, Top 10 Pharma

Beware the "Shiny Object" Syndrome

"Cutting-edge technology is seductive, but match the tool to the question. I've seen teams select ultra-complex vascularized organoids for simple toxicity screening—massive overkill that slowed timelines and inflated costs. Sometimes a simpler, more validated 2D or basic 3D model is the right answer. The best technology is the one that reliably answers your specific biological question at acceptable cost and speed, not the one that wins innovation awards."
Tom Anderson, Head of NAM Strategy, Mid-Size Biotech

Vendor Relationships are Partnerships, Not Transactions

"Our most successful vendor partnerships involve deep collaboration: joint troubleshooting, protocol co-development, regular business reviews, transparent communication about what's working and what isn't. Treat vendors as extensions of your team—share context about why studies matter, provide constructive feedback, pay invoices on time. The best vendors become invested in your success and will go above-and-beyond when you have urgent needs. Adversarial relationships with vendors optimizing for every contract clause lead to minimum-compliance service."
Dr. Priya Patel, CSO, Contract Research Organization

Build vs. Buy: The Hidden Costs of Insourcing

"We purchased an organ-chip platform thinking we'd save money vs. CRO fees. Reality: $400K capital + $200K/year consumables + 2 FTE scientists + 6 months learning curve + ongoing maintenance. Our effective cost-per-data-point was HIGHER than CRO pricing for first 2 years. Insourcing makes sense ONLY if: (1) high sustained volume (>500 samples/year), (2) need for IP protection, (3) rapid iteration requiring daily access, or (4) developing proprietary models. For most pharmaceutical programs, hybrid model works best: CRO for routine/high-volume, in-house for strategic/proprietary work."
Mark Sullivan, Director Translational Sciences, Biotech Company

Regulatory Path Determines Vendor Requirements

"If your organoid data will support regulatory submissions (IND, NDA), vendor qualification requirements are an order of magnitude higher. You MUST audit their quality systems, verify GLP-compliance or GLP-like practices, confirm data integrity controls, and document vendor qualification per 21 CFR Part 11. Don't wait until mid-program to discover your vendor's data management doesn't meet Part 11 requirements—that's a program-killer. For exploratory research, requirements are lighter, but if there's ANY chance of regulatory use, qualify vendors to the higher standard from day one."
Dr. Lisa Chen, Regulatory Affairs Lead, Gene Therapy Company